Oncotarget

Research Papers:

Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta‑analysis of individual studies

Ji Cheng, Jinbo Gao, Xiaoming Shuai and Kaixiong Tao _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:24314-24325. https://doi.org/10.18632/oncotarget.8237

Metrics: PDF 1691 views  |   HTML 1823 views  |   ?  


Abstract

Ji Cheng1, Jinbo Gao1, Xiaoming Shuai1, Kaixiong Tao1

1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence to:

Kaixiong Tao, e-mail: [email protected]

Keywords: SALL4, ZNF217, prognosis, solid malignancies, meta-analysis

Received: December 01, 2015     Accepted: February 21, 2016     Published: March 21, 2016

ABSTRACT

Background: SALL4 and ZNF217 have been widely acknowledged as pivotal effectors stimulating embryonic immortalization as well as oncogenicity. Nevertheless, their prognostic worthiness towards solid tumors remains obscure. Hence we performed this comprehensive meta-analysis aiming to unveil the survival significance of both aberrantly expressed proteins.

Results: Overall we included 22 eligible entries comprising of 3093 participants. Over-expression of SALL4 and ZNF217 were negatively correlated with clinical prognosis of 3-year, 5-year, 10-year and disease-free survival in solid malignancies, irrespective of cancer types, source regions, mean-age and sex predominance. Results of sensitivity analysis additionally verified the stability of the pooled outcomes. No publication bias was observed on the basis of Egger’s test and Begg’s test.

Methods: Studies were eventually included via database searching and rigorous eligibility appraisal. Data extraction and methodological assessment were implemented under a standard manner. Review Manager 5.3 and STATA 12.0 were utilized as statistical platforms following the recommendations by Cochrane Collaboration protocols.

Conclusions: Aberrant amplification of SALL4 and ZNF217 serve as unfavorable predictors of survival expectancy among cancer sufferers, revealing great potential as targeted spots in future therapeutics.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8237